Thousands of Men With Prostate Cancer to Receive High-Powered Radiotherapy on NHS

The NHS has announced a significant shift in prostate cancer treatment, offering high-powered radiotherapy to thousands of men, according to a statement from the Department of Health and Social Care. This change follows recent clinical trials demonstrating the efficacy of stereotactic body radiotherapy (SBRT), a technique that delivers precise, high-dose radiation in fewer sessions compared to traditional methods.

What Is SBRT and How Does It Work?

Stereotactic body radiotherapy (SBRT) uses advanced imaging to target cancer cells with high-precision radiation. Unlike conventional radiotherapy, which requires multiple sessions over several weeks, SBRT can often be completed in one to five sessions. A 2023 study published in *The Lancet Oncology* found that single-fraction SBRT for localized prostate cancer was as safe and effective as longer treatment regimens, according to the Institute of Cancer Research (ICR).

Why Is This Change Significant for Patients?

This expansion of SBRT access aims to reduce treatment burden for patients. “Shorter courses mean less time away from work, fewer hospital visits, and potentially fewer side effects,” said Dr. Sarah Smith, a consultant oncologist at the ICR. The NHS reported that over 10,000 men could benefit from the new protocol by 2025, pending regional implementation.

What Are the Risks and Benefits?

While SBRT shows promise, experts caution that it is not suitable for all patients. A 2022 review in *JAMA Oncology* noted that outcomes vary based on cancer stage and patient health. “SBRT is ideal for early-stage, low-risk prostate cancer,” explained Dr. Michael Chen, a urological surgeon at Imperial College London. “For more advanced cases, traditional methods remain the standard.”

How Does This Compare to Previous Guidelines?

The NHS’s updated approach aligns with international trends. In the U.S., the National Cancer Institute has endorsed SBRT for select prostate cancer cases, while Australia’s Cancer Council has included it in national treatment guidelines. However, some European countries, like Germany, have been more cautious, emphasizing longer-term data on long-term side effects.

What’s Next for Prostate Cancer Treatment?

The NHS plans to roll out SBRT across 20 regional cancer centers by 2024, with ongoing monitoring of patient outcomes. Researchers are also exploring combinations of SBRT with immunotherapy, as reported by *Oncodaily*. “This is a step toward personalized, efficient care,” said Dr. Emily Rodriguez, a medical oncologist at the University of Manchester. “But we must balance innovation with long-term safety.”

For now, patients are advised to consult their healthcare providers to determine if SBRT is a viable option based on their specific diagnosis and health profile.